Home » Study Demonstrates Feasibility of Tracking Mutations in Multiple Genes with Circulating Tumor DNA

Study Demonstrates Feasibility of Tracking Mutations in Multiple Genes with Circulating Tumor DNA

May 30, 2012
|
staff reporter

NEW YORK (GenomeWeb News) – In Science Translational Medicine, researchers from the UK and the US have demonstrated the feasibility of doing blood-based 'liquid biopsies' using a targeted deep sequencing strategy that can uncover mutations in several genes using tumor DNA that is circulating in the bloodstream.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Bit of Uncertainty

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Effect of Sex

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Better Microbes

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

This Week in PNAS

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.

What's Popular?

In Clinical Sequencing

  1. Thermo Fisher Next-Gen Sequencing Panel Wins FDA Approval as Companion Test

  2. Bidens Launch Cancer Initiative to Preserve Momentum, Push Forward Moonshot Priorities

  3. After Approval of Next-Gen Sequencing CDx Panel, Thermo Fisher Seeks Rapid Expansion of Indications

    Premium

  4. Genomics England to Adopt Illumina's BaseSpace Variant Interpreter for Cancer Samples

  5. Studies Seek to Make Case for Sequencing Healthy Individuals, But Questions Remain

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.